Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Date:11/20/2008

n a cohort of women who have been heavily, but unsuccessfully, pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo.

Overall compliance with study medication was excellent with 90% of prescribed doses taken. The most common side effects experienced by women in the Phase 1B clinical trial were mild diarrhea and nausea.

"We are encouraged by the results of the Company's second Phase 1 trial in women with advanced breast cancer," said Isaac Cohen, Chairman and CEO of Bionovo. "There are currently over 160,000 women in the United States living with advanced breast cancer who are eagerly awaiting an oral anticancer drug with minimal side effects and the ability to extend life without profoundly diminishing their quality of life. We believe BZL101 may be an important new anticancer agent because its biological selectivity allows the drug to kill cancer cells without affecting normal cells. This will lead to a dramatically lower side effect profile."

Phase 2 Clinical Trial

The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies.

The trial is open at the following clinical sites under the directorship of the listed investigators:


    Institution                                    Site Principle Investigator
    California Cancer Care Inc.,
     Greenbrae/San Mateo, California                      Dr. Peter Eisenberg
    Columbia Presbyterian Medical Center,
     New York, New York                                   Dr. Dawn Hershman
    Comprehensive Cancer Center at Desert Regional
     Medical Center, Palm Springs, California             Dr. Gail Leichman
    Duke University, Durham, North Carolina               Dr. Gretchen Kimmick
    Lynn Regional Cancer Center, Boca Raton, Florid
'/>"/>
SOURCE  Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013   Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options.  ...
(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter.  The Facebook homepage ... Says CEO Bruce J. ...
(Date:5/22/2013)... TORONTO , May 22, 2013  Generex ... three presentations demonstrating the superiority of the AE37 breast ... Express, Inc. ( www.antigenexpress.com ). The presentations will be ... of Clinical Oncology (ASCO) to be held in ... 4, 2013. The presentation entitled " Booster ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Medifirst Solutions, Inc. Announces Update To Shareholders 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4
... N. J. ,Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical ... developer, manufacturer and marketer of medical devices worldwide, today ... hand-held M series ultrasound platforms at the American Society ... October 14-18, 2011. The M7 ...
... MAHWAH, N.J., Oct. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray ... a leading developer, manufacturer and marketer of medical ... A3 anesthesia system, an expansion of its A ... that complements Mindray,s broad range of ultrasound and ...
Cached Medicine Technology:Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA 2Mindray Announces Expansion of its A Series Anesthesia Portfolio 2
(Date:5/22/2013)... Over the next two decades, the cost of treating ... than double, topping more than $180 billion a year, ... the increase: an aging population. The report, from the ... was published May 22 in the journal Stroke ... system," Dr. Bruce Ovbiagele, chairman of the department of ...
(Date:5/22/2013)... Award Presented at the 2013 Annual ... here: http://bit.ly/13DkFfk , Merrill Corporation is pleased ... Product/Service of the Year” at the 7th M&A Advisor ... Hotel in Palm Beach, Florida. , Merrill DataSite ... solution that optimizes the due diligence process and ...
(Date:5/22/2013)... 22, 2013 Hurricane preparation isn’t just ... That’s why Amica Insurance is reminding everyone ... upcoming hurricane season. , “An important part of hurricane ... a senior assistant vice president at Amica Insurance. “The ... the threat of a storm.” , Flood damage is ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Finding trustworthy, loving ... parents can do for their children. To help parents in ... chock-full of information about their nurturing programs, staff and ... captures the warm spirit of Paty’s Daycare,” said Patricia “Auntie ... feel welcome when you visit the new website, from the ...
(Date:5/22/2013)... May 22, 2013 Unknown to the citizens ... at 30 mph. Minutes before it struck, the city’s ... nearing threat. This gave them time to reach safety and ... is proud to provide a product that will increase ... Wheelock SAFEPATH® SP40S Emergency Evacuation System provides employees ...
Breaking Medicine News(10 mins):Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2Health News:Paty’s Daycare Launches New Website to Connect with Parents in Need of Nurturing Child Care 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
... for laboratories looking for time and cost ... operation in terms of easy reagent cassette ... on-board stability., ,URISYS 2400 is a ... capability for medium to high volume laboratories ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
Acufex arthroscopic electrodes are insulated for use in all fluids and come in boxes of 10....
... The Assistant Free ... retractors utilizing Velcro® straps. ... of the surgeon's operative ... personnel. Three retractor styles ...
Medicine Products: